The failed theratope vaccine: 10 years later

Journal of the American Osteopathic Association

Volumn 112, Issue 8, 2012, Pages 482-483

  Zeichner, Simon B ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; SIALYL TN ANTIGEN KEYHOLE LIMPET HEMOCYANIN CONJUGATE; SIALYL-TN ANTIGEN-KEYHOLE-LIMPET HEMOCYANIN CONJUGATE;

BREAST TUMOR; FEMALE; HUMAN; IMMUNOLOGY; LETTER; TREATMENT FAILURE;

BREAST NEOPLASMS; CANCER VACCINES; FEMALE; HUMANS; TREATMENT FAILURE;

EID: 84867183647     PISSN: 00986151     EISSN: 19451997     Source Type: Journal    
DOI: None     Document Type: Letter

References (13)

1. Holmberg LA, Sandmaier BM. Theratope vaccine (ST n-KLH) [review]. Expert Opin Biol Ther. 2001;1(5):881-891.
2. MacLean GD, Reddish MA, Koganty RR, Longenecker BM. Antibodies against mucin-associated sial yl-Tne pitopescorre late with surviv al of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. J Immunother Emphasis Tumor Immunol. 1996;19(1):59-68.
3. Reddish MA, MacLean GD, Poppema S, Berg A, Longenecker BM. Pre-immunoth e ra py seru m CA27.29 (MUC-1) mucin level and CD69+ lymphocytes correlate with effects of Theratope sialyl-Tn-KLH cancer vaccine in active specific immunotherapy. Cancer Immunol Immunother. 1996;42(5):303-309.
4. MacLean GD, Miles DW, Rubens RD, Reddish MA, Longenecker BM. Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with lowdose intravenous cyclophosphamide. J Immunother Emphasis Tumor Immunol. 1996;19(4): 309-316.
5. Miles D, Papazisis K. Rationale for the clinical development of STn-KLH (Theratope) and anti-MUC-1 vaccines in breast cancer [review]. Clin Breast Cancer. 2003;3(suppl 4):S134-S138.
6. Sandmaier BM, Oparin DV, Holmberg LA, Reddish MA, MacLean GD, Longenecker BM. Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with Theratope STn-KLH cancer vaccine. J Immunother. 1999;22(1):54-66.
7. Hadden JW. The immunology and immuno-therapy of breast cancer: an update [review]. Int J Immunopharmacol. 1999;21(2):79-101.
8. Biomira and Merck KGaA announce Phase III Theratope(R) vaccine trial does not meet primary endpoints. PR Newswire Web site. http://www.prnewswire.com/news-releases/biomira-and-merck-kgaa-announce-phase-iii-theratoper-vaccine-trial-does-not-meet-primary-endpoints-71326627.html. Accessed May 29, 2012.
9. Miles D, Roché H, Martin M, et al; Theratope(r) Study Group. Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer [published online ahead of print May 14, 2011]. Oncologist. 2011;16(8):1092-1100.
10. Braun DP, Crist KA, Shaheen F, Staren ED, Andrews S, Parker J. Aromatase inhibitors increase the sensitivity of human tumor cells to monocytemediated, antibody-dependent cellular cytotoxicity. Am J Surg. 2005;190(4):570-571.
11. Gilewski TA, Ragupathi G, Dickler M, et al. Immunization of high-risk breast cancer patients with clustered sTn-KLH conjugate plus the immunologic adjuvant QS-21. Clin Cancer Res. 2007;13(10): 2977-2985.
12. Kantoff PW, Higano CS, Shore ND, et al; IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411-422.
13. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma [published online ahead of print June 5, 2010]. N Engl J Med. 2010;363(8):711-723.